Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 11, 2023
Product Development
Building on dermatology’s recent success
Targets, mechanisms and indications that stand to benefit from the surging interest in dermatology
BioCentury | May 11, 2022
Product Development
May 10 Quick Takes: ‘molecular machines’ company MOMA lands $150M series B
Plus GPCR play Domain raises $42M and updates from OncoHost, Eisai, UCB, Idorsia and more
BioCentury | Oct 11, 2021
Deals
With CVR, Pacira’s deal for Flexion could nearly double in size
Analgesics company Pacira adds marketed osteoarthritis therapy, with more upside for Flexion shareholders
BioCentury | Jun 5, 2021
Product Development
What Tmunity is and isn’t changing after deaths that grounded its PSMA CAR program
Same targets, but more stringent patient selection protocols and optimized cell engineering
BioCentury | Jun 30, 2020
Product Development
Low-stakes 2018 deal with Regeneron leads to bump for Kiniksa on pericarditis readout
BioCentury | Apr 11, 2020
Product Development
Master protocols emerge as a critical clinical tool against COVID-19
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
BioCentury | Mar 19, 2020
Product Development
Roivant pivots towards ARDS in COVID-19; plus Italian studies of repurposed anti-inflammatories, vaccine updates and more
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
BioCentury | Oct 7, 2019
Tools & Techniques
Locus co-founders open door to new CRISPR systems
A different type of CRISPR system that works in human cells creates new therapeutic opportunities
BioCentury | Sep 25, 2019
Tools & Techniques
Locus co-founders open door to new CRISPR systems
A different type of CRISPR system that works in human cells creates new therapeutic opportunities
BioCentury | Aug 23, 2019
Targets & Mechanisms
New targets in osteoarthritis are about more than just pain
With mechanistic insights and a nudge from FDA, companies are taking OA past analgesics into disease-modifying targets
Items per page:
1 - 10 of 85